8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 10, 2026·SEC
Material company update
Mar 23, 2026·SEC
Crinetics Pharmaceuticals, Inc.(CRNX)Earnings, Financials & Key Ratios
CRNX•NASDAQ
Price updated Jun 19, 2026
AboutCrinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Show more
- Revenue$8M+640.7%
- EBITDA-$513M-52.6%
- Net Income-$465M-55.9%
- EPS (Diluted)-4.95-34.1%
- Gross Margin86.02%-14.0%
- EBITDA Margin-6664.23%+79.4%
- Operating Margin-6714.77%+79.4%
- Net Margin-6046.22%+78.9%
- ROE-40.17%-25.4%
CRNX Key Insights
Crinetics Pharmaceuticals, Inc. (CRNX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 155.3%
✗Weaknesses
- ✗Profits declining 44.5% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 16.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CRNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRNX Price & Volume
Crinetics Pharmaceuticals, Inc. (CRNX) stock price & volume — 10-year historical chart
Loading chart...
CRNX Growth Metrics
Crinetics Pharmaceuticals, Inc. (CRNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years155.27%
3 Years17.56%
TTM2277.5%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-51.22%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-34.55%
Return on Capital
10 Years-46.05%
5 Years-43.8%
3 Years-41.9%
Last Year-42.61%
CRNX Recent Earnings
Crinetics Pharmaceuticals, Inc. (CRNX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 7/12 qtrs (78%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.23-0.8%
$1.22
Rev
$11M+26.1%
$9M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.29+5.8%
$1.37
Rev
$6M+37.2%
$4M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.38-8.7%
$1.27
Rev
$143,000-96.7%
$4M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.23-8.8%
$1.13
Rev
$1M+161.7%
$394,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.23vs $1.22-0.8% | $11Mvs $9M+26.1% |
| Q1 2026 | Feb 26, 2026 | $1.29vs $1.37+5.8% | $6Mvs $4M+37.2% |
| Q4 2025 | Nov 6, 2025 | $1.38vs $1.27-8.7% | $143,000vs $4M-96.7% |
| Q3 2025 | Aug 7, 2025 | $1.23vs $1.13-8.8% | $1Mvs $394,000+161.7% |
Based on last 12 quarters of dataView full earnings history →
CRNX Peer Comparison
Crinetics Pharmaceuticals, Inc. (CRNX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 CHRS | 181.17M | 1.48 | -1.02 | -84.2% | -323.49% | -174.71% | 0.66 | |
 ACVA | 1.13B | 6.48 | -16.62 | 19.22% | -7.97% | -14.27% | 0.44 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 ESPR | 654.91M | 3.15 | -28.64 | 21.31% | -1.77% | |||
 XNCR | 927M | 12.64 | -10.19 | 13.65% | -185.71% | -28.77% | 0.30 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% |
Compare CRNX vs Peers
Crinetics Pharmaceuticals, Inc. (CRNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRNX Income Statement
Crinetics Pharmaceuticals, Inc. (CRNX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.04M | 2.43M | 1.19M | 71K | 1.08M | 4.74M | 4.01M | 1.04M | 7.7M | 18.07M |
Revenue Growth % | 247.2% | 18.73% | -50.86% | -94.05% | 1418.31% | 339.42% | -15.28% | -74.11% | 640.71% | 2277.5% |
Cost of Goods Sold | 9.23M | 24.48M | 1.11M | 57M | 0 | 0 | 0 | 0 | 1.08M | 200K |
COGS % of Revenue | 451.49% | 1008.2% | 93.29% | 80278.87% | - | - | - | - | 13.98% | - |
Gross Profit | -7.19M▲ 0% | -22.05M▼ 206.8% | 80K▲ 100.4% | -56.93M▼ 71258.8% | 1.08M▲ 101.9% | 4.74M▲ 339.4% | 4.01M▼ 15.3% | 1.04M▼ 74.1% | 6.62M▲ 537.2% | 17.87M▲ 0% |
Gross Margin % | -351.49% | -908.2% | 6.71% | -80178.87% | 100% | 100% | 100% | 100% | 86.02% | 98.89% |
Gross Profit Growth % | -59.34% | -206.78% | 100.36% | -71258.75% | 101.89% | 339.42% | -15.28% | -74.11% | 537.15% | - |
Operating Expenses | 9.13M | 28.71M | 53.83M | 18.03M | 108.78M | 172.62M | 226.62M | 339.89M | 523.39M | 563.61M |
OpEx % of Revenue | 446.31% | 1182.45% | 4512.32% | 25388.73% | 10090.91% | 3644.06% | 5647.17% | 32713.47% | 6800.79% | - |
Selling, General & Admin | 1.94M | 6.66M | 13.52M | 18.03M | 24.52M | 42.39M | 58.09M | 99.74M | 191.33M | 206.64M |
SG&A % of Revenue | 94.82% | 274.26% | 1133.19% | 25388.73% | 2275.05% | 894.95% | 1447.65% | 9599.33% | 2486.11% | - |
Research & Development | 9.23M | 24.48M | 41.51M | 57.6M | 84.25M | 130.22M | 168.53M | 240.16M | 332.06M | 355.9M |
R&D % of Revenue | 451.49% | 1008.2% | 3479.13% | 81123.94% | 7815.86% | 2749.1% | 4199.53% | 23114.15% | 4314.68% | - |
Other Operating Expenses | -48K | 1.59M | -1.19M | -57.6M | 0 | 0 | 0 | 0 | 0 | 1000K |
Operating Income | -9.13M▲ 0% | -28.71M▼ 214.6% | -53.83M▼ 87.5% | -74.95M▼ 39.2% | -107.7M▼ 43.7% | -167.88M▼ 55.9% | -222.61M▼ 32.6% | -338.85M▼ 52.2% | -516.77M▼ 52.5% | -545.74M▲ 0% |
Operating Margin % | -446.31% | -1182.45% | -4512.32% | -105567.61% | -9990.91% | -3544.06% | -5547.17% | -32613.47% | -6714.77% | -3020.32% |
Operating Income Growth % | -51.01% | -214.56% | -87.5% | -39.23% | -43.69% | -55.88% | -32.6% | -52.22% | -52.5% | - |
EBITDA | -9M | -28.24M | -52.72M | -74M | -106.78M | -166.9M | -221.51M | -336.07M | -512.88M | -541.62M |
EBITDA Margin % | -440.05% | -1163.06% | -4419.03% | -104232.39% | -9905.38% | -3523.31% | -5519.81% | -32345.43% | -6664.23% | -2997.49% |
EBITDA Growth % | -51.19% | -213.8% | -86.69% | -40.38% | -44.29% | -56.3% | -32.72% | -51.72% | -52.61% | -45.01% |
D&A (Non-Cash Add-back) | 128K | 471K | 1.11M | 948K | 922K | 983K | 1.1M | 2.79M | 3.89M | 4.13M |
EBIT | -9.15M | -27.11M | -53.83M | -74.95M | -107.7M | -167.88M | -222.61M | -338.85M | -516.77M | -545.74M |
Net Interest Income | 18K | 0 | 3.46M | 991K | 157K | 4.32M | 13.44M | 41.44M | 51.99M | 49.82M |
Interest Income | 26K | 1.75M | 3.46M | 991K | 157K | 4.32M | 13.44M | 41.44M | 51.99M | 49.82M |
Interest Expense | 8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -30K | 1.59M | 3.41M | 1.14M | 61K | 3.96M | 8.08M | 40.45M | 51.63M | 49.53M |
Pretax Income | -9.16M▲ 0% | -27.11M▼ 196.1% | -50.42M▼ 86.0% | -73.81M▼ 46.4% | -107.64M▼ 45.8% | -163.92M▼ 52.3% | -214.53M▼ 30.9% | -298.41M▼ 39.1% | -465.14M▼ 55.9% | -496.21M▲ 0% |
Pretax Margin % | -447.78% | -1116.76% | -4226.49% | -103960.56% | -9985.25% | -3460.38% | -5345.85% | -28720.69% | -6043.88% | -2746.18% |
Income Tax | -40K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180K | 180K |
Effective Tax Rate % | 0.44% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.04% | -0.04% |
Net Income | -9.16M▲ 0% | -27.11M▼ 196.1% | -49.53M▼ 82.7% | -73.81M▼ 49.0% | -107.64M▼ 45.8% | -163.92M▼ 52.3% | -214.53M▼ 30.9% | -298.41M▼ 39.1% | -465.32M▼ 55.9% | -496.39M▲ 0% |
Net Margin % | -447.78% | -1116.76% | -4152.14% | -103960.56% | -9985.25% | -3460.38% | -5345.85% | -28720.69% | -6046.22% | -2747.18% |
Net Income Growth % | -52.13% | -196.11% | -82.68% | -49.01% | -45.83% | -52.28% | -30.88% | -39.1% | -55.93% | -51.22% |
Net Income (Continuing) | -9.16M | -27.11M | -50.42M | -73.81M | -107.64M | -163.92M | -214.53M | -298.41M | -465.32M | -496.39M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.66▲ 0% | -2.23▼ 237.9% | -2.05▲ 8.1% | -2.42▼ 18.0% | -2.80▼ 15.7% | -3.15▼ 12.5% | -3.69▼ 17.1% | -3.69▲ 0.0% | -4.95▼ 34.1% | -4.77▲ 0% |
EPS Growth % | -53.49% | -237.88% | 8.07% | -18.05% | -15.7% | -12.5% | -17.14% | 0% | -34.15% | -34.55% |
EPS (Basic) | -0.66 | -2.23 | -2.05 | -2.42 | -2.80 | -3.15 | -3.69 | -3.69 | -4.95 | - |
Diluted Shares Outstanding | 13.88M | 12.14M | 24.18M | 30.45M | 38.44M | 51.98M | 58.07M | 80.78M | 94.06M | 104.1M |
Basic Shares Outstanding | 13.88M | 12.14M | 24.18M | 30.45M | 38.44M | 51.98M | 58.07M | 80.78M | 94.06M | 104.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CRNX Balance Sheet
Crinetics Pharmaceuticals, Inc. (CRNX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 15.16M | 166.68M | 123.34M | 177.49M | 344.72M | 345.18M | 574.15M | 1.38B | 1.05B | 1.32B |
Cash & Short-Term Investments | 14.19M | 163.88M | 118.39M | 170.88M | 333.71M | 334.43M | 558.55M | 1.35B | 1.03B | 1.29B |
Cash Only | 14.19M | 44.97M | 40.33M | 93.09M | 200.69M | 32.67M | 54.9M | 264.55M | 101.54M | 114.34M |
Short-Term Investments | 0 | 118.9M | 78.07M | 77.79M | 133.01M | 301.75M | 503.66M | 1.09B | 926.35M | 1.18B |
Accounts Receivable | 734K | 0 | 1.38M | 1.83M | 2.03M | 2.42M | 9.35M | 8.47M | 592K | 5.68M |
Days Sales Outstanding | 131.01 | - | 421.6 | 9.42K | 687 | 186.85 | 850.51 | 2.98K | 28.08 | 31.69 |
Inventory | 141K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.02M | 3.06M |
Days Inventory Outstanding | 5.57 | - | - | - | - | - | - | - | 685.9 | 2.32K |
Other Current Assets | 0 | 0 | 1.09M | 1.02M | 0 | 2.54M | 1.58M | 1.71M | 17.84M | 22.36M |
Total Non-Current Assets | 433K | 4.73M | 7.04M | 5.95M | 6.29M | 6.99M | 61.2M | 59.2M | 87.15M | 78.91M |
Property, Plant & Equipment | 400K | 4.23M | 6.46M | 5.41M | 4.72M | 4.99M | 57.43M | 55.58M | 54.79M | 53.29M |
Fixed Asset Turnover | 5.11x | 0.57x | 0.18x | 0.01x | 0.23x | 0.95x | 0.07x | 0.02x | 0.14x | 0.33x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 500K | 500K | 0 | 1.01M | 1.97M | 1.77M | 800K | 800K | 2.4M |
Other Non-Current Assets | 33K | 0 | 82K | 540K | 568K | 37K | 2M | 2.83M | 22.33M | 24.82M |
Total Assets | 15.6M▲ 0% | 171.41M▲ 999.0% | 130.38M▼ 23.9% | 183.44M▲ 40.7% | 351.01M▲ 91.3% | 352.18M▲ 0.3% | 635.35M▲ 80.4% | 1.43B▲ 125.8% | 1.14B▼ 20.8% | 1.4B▲ 0% |
Asset Turnover | 0.13x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 0.00x | 0.01x | 0.01x |
Asset Growth % | 23.8% | 998.95% | -23.94% | 40.7% | 91.35% | 0.33% | 80.41% | 125.79% | -20.85% | 47.53% |
Total Current Liabilities | 897K | 7.92M | 8.34M | 10.49M | 15.99M | 27.72M | 43.94M | 59.68M | 85.07M | 71.09M |
Accounts Payable | 403K | 1.46M | 2.7M | 3.49M | 3.42M | 6.88M | 6.55M | 5.85M | 22.61M | 12.88M |
Days Payables Outstanding | 15.93 | 21.71 | 884.79 | 22.34 | - | - | - | - | 7.67K | 24.15K |
Short-Term Debt | 0 | 0 | 724K | 0 | 0 | 1.05M | 4.17M | 0 | 6.49M | 6.54M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 2.24M | 2.06M | 2.18M | 1.24M | 4.41M |
Other Current Liabilities | 0 | 590K | 2.8M | 4.9M | 7.53M | 8.47M | 16.65M | 10K | 19.16M | 24.61M |
Current Ratio | 16.91x | 21.03x | 14.79x | 16.92x | 21.55x | 12.45x | 13.07x | 23.04x | 12.32x | 18.60x |
Quick Ratio | 16.75x | 21.03x | 14.79x | 16.92x | 21.55x | 12.45x | 13.07x | 23.04x | 12.30x | 18.56x |
Cash Conversion Cycle | 120.65 | - | - | - | - | - | - | - | -6.96K | -21.79K |
Total Non-Current Liabilities | 29.72M | 3.27M | 4.9M | 4.04M | 3.08M | 8.13M | 52.3M | 50.1M | 58.34M | 49.59M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 4.85M | 4.01M | 3.07M | 2.02M | 47.55M | 44.57M | 42.05M | 169.4M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.24M | 9.24M |
Other Non-Current Liabilities | 29.72M | 3.27M | 49K | 23K | 2K | 0 | 0 | 829K | 3.24M | 4.93M |
Total Liabilities | 30.62M | 11.19M | 13.24M | 14.53M | 19.07M | 35.85M | 96.25M | 109.79M | 143.41M | 120.68M |
Total Debt | 0 | 0 | 5.57M | 4.01M | 3.07M | 3.08M | 51.73M | 51.72M | 48.54M | 47.85M |
Net Debt | -14.19M | -44.97M | -34.75M | -89.07M | -197.62M | -29.6M | -3.17M | -212.82M | -52.99M | -66.49M |
Debt / Equity | - | - | 0.05x | 0.02x | 0.01x | 0.01x | 0.10x | 0.04x | 0.05x | 0.04x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.09x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.12x |
Interest Coverage | -1143.63x | - | - | - | - | - | - | - | - | - |
Total Equity | -15.02M▲ 0% | -43.38M▼ 188.8% | 117.14M▲ 370.0% | 168.92M▲ 44.2% | 331.94M▲ 96.5% | 316.33M▼ 4.7% | 539.11M▲ 70.4% | 1.32B▲ 145.7% | 992.08M▼ 25.1% | 1.28B▲ 0% |
Equity Growth % | -142.13% | -188.78% | 370.03% | 44.2% | 96.51% | -4.7% | 70.43% | 145.74% | -25.11% | 46.74% |
Book Value per Share | -1.08 | -3.57 | 4.85 | 5.55 | 8.64 | 6.09 | 9.28 | 16.40 | 10.55 | 12.30 |
Total Shareholders' Equity | -15.02M | -43.38M | 117.14M | 168.92M | 331.94M | 316.33M | 539.11M | 1.32B | 992.08M | 1.28B |
Common Stock | 1K | 24K | 210.79M | 336.51M | 607.58M | 759.43M | 1.19B | 2.28B | 2.41B | 2.83B |
Retained Earnings | -16.27M | -43.38M | -93.8M | -167.61M | -275.25M | -439.17M | -653.7M | -952.11M | -1.42B | -1.55B |
Treasury Stock | 0 | -374.94M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -304K | 61K | 148K | 25K | -382K | -3.93M | 977K | 963K | 1.75M | -2.29M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRNX Cash Flow Statement
Crinetics Pharmaceuticals, Inc. (CRNX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.48M | -19.46M | -46.38M | -62.03M | -88.59M | -115.2M | -166.31M | -225.97M | -377.92M | -414.17M |
Operating CF Margin % | -463.52% | -801.44% | -3887.76% | -87361.97% | -8217.81% | -2432.02% | -4144.21% | -21748.8% | -4910.63% | - |
Operating CF Growth % | -73.35% | -105.29% | -138.35% | -33.73% | -42.82% | -30.05% | -44.36% | -35.88% | -67.24% | -246.94% |
Net Income | -9.16M | -27.11M | -50.42M | -73.81M | -107.64M | -163.92M | -214.53M | -298.41M | -465.32M | -496.39M |
Depreciation & Amortization | 128K | 471K | 887K | 948K | 922K | 983K | 1.1M | 2.79M | 3.89M | 4.13M |
Stock-Based Compensation | 271K | 2.32M | 6.29M | 10.43M | 17.35M | 28.27M | 40.94M | 69.39M | 91.02M | 100.23M |
Deferred Taxes | 0 | 0 | -1.23M | -227K | 422K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 480K | -433K | 222K | 261K | -739K | 850K | -1.86M | -11.37M | -12.36M | -10.31M |
Working Capital Changes | -721K | 5.3M | -2.13M | 376K | 1.1M | 18.61M | 8.04M | 11.63M | 4.84M | -11.82M |
Change in Receivables | 0 | 0 | 0 | 2.72M | 6.29M | 10.99M | 14.65M | 17.54M | -592K | -5.09M |
Change in Inventory | 0 | 0 | 0 | -2.72M | -6.29M | 0 | 0 | 0 | -2.02M | -909K |
Change in Payables | 47K | 7.36M | 696K | 2.72M | 6.29M | 0 | 0 | 0 | 28.98M | 18.27M |
Cash from Investing | -304K | -119.46M | 41.67M | 217K | -56.48M | -173.98M | -200.41M | -574.82M | 173.91M | 7.51M |
Capital Expenditures | -304K | -1.06M | -492K | -186K | -436K | -1.66M | -4.69M | -3.84M | -5.76M | -5.34M |
CapEx % of Revenue | 14.87% | 43.62% | 41.24% | 261.97% | 40.45% | 34.96% | 116.82% | 369.97% | 74.87% | 29.57% |
Acquisitions | 0 | 0 | -1.23M | -227K | 422K | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -118.4M | 1.23M | 227K | -422K | 0 | 0 | 0 | 15.43M | 578K |
Cash from Financing | 11.82M | 170.2M | 67K | 114.57M | 252.68M | 121.96M | 388.94M | 1.01B | 40.61M | 426.05M |
Debt Issued (Net) | -212K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 11.97M | 169.75M | -59K | 114.28M | 249.54M | 117.24M | 369.02M | 970.05M | 40.61M | 426.05M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -59K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 66K | 451K | 126K | 288K | 3.14M | 4.72M | 19.93M | 40.39M | 0 | 0 |
Net Change in Cash | 2.04M▲ 0% | 31.28M▲ 1433.4% | -4.65M▼ 114.9% | 52.76M▲ 1235.4% | 107.61M▲ 104.0% | -167.22M▼ 255.4% | 22.22M▲ 113.3% | 209.65M▲ 843.3% | -163.51M▼ 178.0% | 19.27M▲ 0% |
Free Cash Flow | -9.78M▲ 0% | -20.52M▼ 109.7% | -46.87M▼ 128.4% | -62.21M▼ 32.7% | -89.02M▼ 43.1% | -116.86M▼ 31.3% | -171M▼ 46.3% | -229.81M▼ 34.4% | -383.68M▼ 67.0% | -419.52M▲ 0% |
FCF Margin % | -478.39% | -845.06% | -3929% | -87623.94% | -8258.26% | -2466.98% | -4261.03% | -22118.77% | -4985.5% | -2321.74% |
FCF Growth % | -72.91% | -109.73% | -128.45% | -32.73% | -43.1% | -31.27% | -46.32% | -34.4% | -66.95% | -58.12% |
FCF per Share | -0.70 | -1.69 | -1.94 | -2.04 | -2.32 | -2.25 | -2.94 | -2.84 | -4.08 | -4.03 |
FCF Conversion (FCF/Net Income) | 1.04x | 0.72x | 0.94x | 0.84x | 0.82x | 0.70x | 0.78x | 0.76x | 0.81x | 0.85x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRNX Key Ratios
Crinetics Pharmaceuticals, Inc. (CRNX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -134.32% | -51.61% | -42.98% | -50.57% | -50.16% | -32.02% | -40.17% | -43.96% |
Return on Invested Capital (ROIC) | - | - | - | -69.3% | -75.43% | -59.81% | -40.59% | -30.84% | -37.79% | -37.8% |
Gross Margin | -351.49% | -908.2% | 6.71% | -80178.87% | 100% | 100% | 100% | 100% | 86.02% | 98.89% |
Net Margin | -447.78% | -1116.76% | -4152.14% | -103960.56% | -9985.25% | -3460.38% | -5345.85% | -28720.69% | -6046.22% | -2747.18% |
Debt / Equity | - | - | 0.05x | 0.02x | 0.01x | 0.01x | 0.10x | 0.04x | 0.05x | 0.04x |
Interest Coverage | -1143.63x | - | - | - | - | - | - | - | - | - |
FCF Conversion | 1.04x | 0.72x | 0.94x | 0.84x | 0.82x | 0.70x | 0.78x | 0.76x | 0.81x | 0.85x |
Revenue Growth | 247.2% | 18.73% | -50.86% | -94.05% | 1418.31% | 339.42% | -15.28% | -74.11% | 640.71% | 2277.5% |
Related:CRNX Dividend History·CRNX Revenue History·CRNX Price History·CRNX P/E History·CRNX Financial Ratios·CRNX Institutional Holders
CRNX SEC Filings & Documents
Crinetics Pharmaceuticals, Inc. (CRNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRNX Frequently Asked Questions
Crinetics Pharmaceuticals, Inc. (CRNX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Crinetics Pharmaceuticals, Inc. (CRNX) reported $18.1M in revenue for fiscal year 2025. This represents a 2968% increase from $0.6M in 2016.
Crinetics Pharmaceuticals, Inc. (CRNX) grew revenue by 640.7% over the past year. This is strong growth.
Crinetics Pharmaceuticals, Inc. (CRNX) reported a net loss of $496.4M for fiscal year 2025.
Dividend & Returns
Crinetics Pharmaceuticals, Inc. (CRNX) has a return on equity (ROE) of -40.2%. Negative ROE indicates the company is unprofitable.
Crinetics Pharmaceuticals, Inc. (CRNX) had negative free cash flow of $419.5M in fiscal year 2025, likely due to heavy capital investments.